Sie sind hier: Startseite Reseachers Thomas Reinheckel

Thomas Reinheckel

Reinheckel, Thomas
Prof. Dr. med.
Stefan-Meier Str. 17, D-79104 Freiburg
email: thomas.reinheckel[a]
Current position

Full Professor (W3) of Molecular Medicine, Institute of Molecular Medicine and Cell Research




Research topic in GRK 2606: Proteases for essential lysosome functions

University training and degree(s)

1989-1996      Study of Medicine, University of Magdeburg and Albert Einstein College of Medicine, N.Y.C. USA
1993-1994      Academic year at the Dept. of Biochemistry and Molecular Biology; Albany N.Y. USA
Advanced academic qualifications
2007                Habilitation in Molecular Medicine, University of Freiburg
1997                Dissertation in Medicine, University of Magdeburg
Postgraduate professional career
Since 2013      Professor (W3) of Molecular Medicine / Cellular Pathomechanisms,
                        Institute of Molecular Medicine and Cell Research Freiburg
2002-2012       Group Leader; Institute of Molecular Medicine and Cell Research Freiburg
1999-2002       Postdoc; Institute of Molecular Medicine and Cell Research Freiburg
1996-1999       Internship / Residency Dept. of General Surgery, University Hospital Magdeburg
since 2019       Member BIOSS Centre for Biological Signalling Studies Freiburg
since 2018       Member of foundation council of the FREY-WERLE endowment
since 2010       Board Member of SFB 850 - Control of Cell Motility in Morphogenesis, Cancer
                        Invasion and Metastasis, Freiburg
since 2008       Coordinator Curriculum BSc/MSc Program Molecular Medicine, Freiburg
since 2007       Principal Investigator Comprehensive Cancer Center Research Program - CCCF
2007-2019       Associate Member BIOSS Centre for Biological Signalling Studies Freiburg
since 2006       Principal Investigator Spemann Graduate School for Biology and Medicine-SGBM
2015-2017       President of the International Proteolysis Society (IPS)
2013-2015       Council Member and Vice President of the International Proteolysis Society
2011                Offer of a professorship of Biochemistry, Bonn
2011                Offer of a professorship of Biochemistry, Frankfurt
2007                Habilitation award by the Funds of Chemical Industry         
1993-1994       Fellowship Biomedical Sciences Exchange Program between North America
                        and Europe                
1991-1996       Fellowship of the Hans-Böckler-Foundation 


10 important publications

  1. Hillebrand, L.E., Wickberg, S.M., Gomez-Auli, A., Follo, M., Maurer, J., Busch, H., Boerries, M., Reinheckel, T. (2019). MMP14 empowers tumor-initiating breast cancer cells under hypoxic nutrient-depleted conditions. FASEB J. 33, 4124-4140.
  2. Köhler, M., Ehrenfeld, S., Halbach, S., Lauinger, M., Burk, U., Reischmann, N., Cheng, S., Spohr, C., Uhl, F.M., Köhler, N., Ringwald, K., Braun, S., Peters, C., Zeiser, R., *Reinheckel, T., *Brummer, T. (2019). B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model. Oncogene 38, 1324-1339. *shared senior
  3. Martínez-Fábregas, J., Prescott, A., van, Kasteren, S., Pedrioli, D.L., McLean, I., Moles, A., Reinheckel, T., Poli, V., Watts, C. (2018). Lysosomal protease deficiency or substrate overload induces an oxidative-stress mediated STAT3-dependent pathway of lysosomal homeostasis. Nat. Commun. 9, 5343ff.
  4. Kern, U., Wischnewski, V., Biniossek, ML., Schilling, O., Reinheckel, T. (2015). Lysosomal protein turnover contributes to the acquisition of TGFβ-1 induced invasive properties of mammary cancer cells. Mol. Cancer 14, 39ff.
  5. Tholen, M., Hillebrand, L.E., Tholen, S., Sedelmeier, O., Arnold, S.J., Reinheckel, T. (2014). Out-of-frame start codons prevent translation of truncated nucleo-cytosolic cathepsin L in vivo. Nat. Commun. 5, 4931-4941.
  6. Bengsch, F., Buck, A., Gunther, S.C., Seiz, J.R., Tacke, M., Pfeifer, D., von, Elverfeldt, D., Sevenich, L., Hillebrand, L.E., Kern, U., Sameni, M., Peters, C., Sloane, B.F., Reinheckel, T. (2014). Cell type-dependent pathogenic functions of overexpressed human cathepsin B in murine breast cancer progression. Oncogene 33, 4474-4484.
  7. Sevenich, L., Schurigt, U., Sachse, K., Gajda, M., Werner, F., Muller, S., Vasiljeva, O., Schwinde, A., Klemm, N., Deussing, J., Peters, C., Reinheckel, T. (2010). Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc. Natl. Acad. Sci. U.S.A. 107, 2497-2502.
  8. Reiser, J., Adair, B., Reinheckel, T. (2010). Specialized roles for cysteine cathepsins in health and disease J. Clin. Invest. 120, 3421-3431.
  9. Vasiljeva, O., Papazoglou, A., Kruger, A., Brodoefel, H., Korovin, M., Deussing, J., Augustin, N., Nielsen, B.S., Almholt, K., Bogyo, M., Peters, C., Reinheckel, T. (2006). Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res. 66, 5242-5250.
  10. 10. Stypmann, J., Glaser, K., Roth, W., Tobin, D.J., Petermann, I., Matthias, R., Mönnig, G., Haverkamp, W., Breithardt, G., Schmahl, W., Peters, C., Reinheckel, T. (2002). Dilated cardiomyopathy in mice deficient for the lysosomal cysteine peptidase cathepsin L. Proc. Natl. Acad. Sci. U.S.A. 99, 6234-6239.